UniSA Allied Health & Human Performance, University of South Australia, Adelaide, SA 5001, Australia.
Faculty of Informatics and Science, University of Oradea, 410087 Oradea, Romania.
Int J Mol Sci. 2023 Dec 8;24(24):17258. doi: 10.3390/ijms242417258.
Tumour repopulation during treatment is a well acknowledged yet still challenging aspect of cancer management. The latest research results show clear evidence towards the existence of cancer stem cells (CSCs) that are responsible for tumour repopulation, dissemination, and distant metastases in most solid cancers. Cancer stem cell quiescence and the loss of asymmetrical division are two powerful mechanisms behind repopulation. Another important aspect in the context of cancer stem cells is cell plasticity, which was shown to be triggered during fractionated radiotherapy, leading to cell dedifferentiation and thus reactivation of stem-like properties. Repopulation during treatment is not limited to radiotherapy, as there is clinical proof for repopulation mechanisms to be activated through other conventional treatment techniques, such as chemotherapy. The dynamic nature of stem-like cancer cells often elicits resistance to treatment by escaping drug-induced cell death. The aims of this scoping review are (1) to describe the main mechanisms used by cancer stem cells to initiate tumour repopulation during therapy; (2) to present clinical evidence for tumour repopulation during radio- and chemotherapy; (3) to illustrate current trends in the identification of CSCs using specific imaging techniques; and (4) to highlight novel technologies that show potential in the eradication of CSCs.
肿瘤在治疗过程中的再增殖是癌症管理中一个公认但仍然具有挑战性的方面。最新的研究结果表明,在大多数实体瘤中,癌症干细胞(CSC)是肿瘤再增殖、扩散和远处转移的罪魁祸首,这一点已经得到明确的证据支持。CSC 的静止和不对称分裂的丧失是再增殖背后的两个强大机制。在癌症干细胞的背景下,另一个重要的方面是细胞可塑性,它在分割放疗期间被触发,导致细胞去分化,从而重新激活干细胞样特性。治疗过程中的再增殖不仅限于放射治疗,因为有临床证据表明,通过其他常规治疗技术,如化疗,可以激活再增殖机制。类干细胞癌细胞的动态特性常常通过逃避药物诱导的细胞死亡来引发对治疗的耐药性。本综述的目的是:(1)描述癌症干细胞在治疗过程中启动肿瘤再增殖的主要机制;(2)介绍放射和化学治疗过程中肿瘤再增殖的临床证据;(3)说明使用特定成像技术识别 CSC 的当前趋势;(4)强调显示出根除 CSC 潜力的新技术。